Ultragenyx Pharmaceutical Inc. RARE
$26.49
+0.42%
at last close
Recent SEC Filings
| Form | Description | Filed | Document |
|---|---|---|---|
| 8-K | 8-K | 2026-08-11 | View → |
| 10-Q | 10-Q | 2026-08-05 | View → |
| 8-K | 8-K | 2026-08-04 | View → |
| 4 | 4 | 2026-08-04 | View → |
| 4 | 4 | 2026-08-04 | View → |
| 4 | 4 | 2026-07-06 | View → |
| 4 | 4 | 2026-06-15 | View → |
| 4 | 4 | 2026-06-15 | View → |
| 4 | 4 | 2026-06-01 | View → |
| 4 | 4 | 2026-05-18 | View → |
| 4 | 4 | 2026-05-18 | View → |
| 4 | 4 | 2026-05-18 | View → |
| 4 | 4 | 2026-05-18 | View → |
| 4 | 4 | 2026-05-18 | View → |
| 4 | 4 | 2026-05-18 | View → |
| 4 | 4 | 2026-05-18 | View → |
| 8-K | 8-K | 2026-05-18 | View → |
| 4 | 4 | 2026-05-06 | View → |
| 10-Q | 10-Q | 2026-05-06 | View → |
| 8-K | 8-K | 2026-05-05 | View → |
| 4 | 4 | 2026-05-04 | View → |
| 4 | 4 | 2026-04-24 | View → |
| 4 | 4 | 2026-04-20 | View → |
| 4 | 4 | 2026-04-20 | View → |
| 4 | 4 | 2026-04-20 | View → |
| 4 | 4 | 2026-04-20 | View → |
| 4 | 4 | 2026-04-20 | View → |
| 4 | 4 | 2026-04-20 | View → |
| 4 | 4 | 2026-04-20 | View → |
| 4 | 4 | 2026-04-02 | View → |
| 8-K | 8-K | 2026-04-02 | View → |
| 8-K | 8-K | 2026-03-30 | View → |
| DEF 14A | DEFINITIVE PROXY STATEMENT | 2026-03-27 | View → |
| 8-K | 8-K | 2026-03-12 | View → |
| 4 | 4 | 2026-03-10 | View → |
| 4 | 4 | 2026-03-03 | View → |
| 4 | 4 | 2026-03-03 | View → |
| 4 | 4 | 2026-03-03 | View → |
| 4 | 4 | 2026-03-03 | View → |
| 4 | 4 | 2026-03-03 | View → |
Filings are sourced directly from the SEC's EDGAR system. Annual reports (10-K) and quarterly reports (10-Q) carry the full financial statements; 8-K filings disclose material events between reports; Form 4 filings record insider purchases and sales.
Key Stats
- Last Close
- $26.49
- Market Cap
- $2.65 billion
- 52-Week Range
- $18.29 – $39.89
- Average Volume
- 1.95 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.